Search research articles
Contact Us
Filters
Showing results (11-20 of 204) with videos related to
Page
of 21
Sort By:
Expert Review of Hematology
|
April 22, 2014
The role of pacritinib in the management of myelofibrosis
Vu H Duong, Rami S Komrokji
Hematology/Oncology Clinics of North America
|
April 3, 2010
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
Rami S Komrokji, Alan F List
Current Hematology Reports
|
May 4, 2005
The clinical implications of the World Health Organization's classification of myelodysplastic syndromes
Rami S Komrokji, John M Bennett
Expert Opinion on Biological Therapy
|
December 2, 2004
The colony-stimulating factors: use to prevent and treat neutropenia and its complications
Rami S Komrokji, Gary H Lyman
Therapeutic Advances in Hematology
|
January 28, 2021
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Virginia O Volpe, Rami S Komrokji
Hematology (Amsterdam, Netherlands)
|
September 29, 2005
The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment
John M Bennett, Rami S Komrokji
Current Hematologic Malignancy Reports
|
April 29, 2010
Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification
Rami S Komrokji, John M Bennett
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Andrew T Kuykendall, Rami S Komrokji
Current Pharmaceutical Design
|
May 11, 2012
Lenalidomide for treatment of myelodysplastic syndromes
Rami S Komrokji, Alan F List
Expert Review of Hematology
|
June 15, 2018
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
Jamile M Shammo, Rami S Komrokji
Page
of 21
Search research articles
Search
Showing results (11-20 of 204) with videos related to
Sort By:
Page
of 21
Expert Review of Hematology
|
April 22, 2014
The role of pacritinib in the management of myelofibrosis
Vu H Duong, Rami S Komrokji
Hematology/Oncology Clinics of North America
|
April 3, 2010
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
Rami S Komrokji, Alan F List
Current Hematology Reports
|
May 4, 2005
The clinical implications of the World Health Organization's classification of myelodysplastic syndromes
Rami S Komrokji, John M Bennett
Expert Opinion on Biological Therapy
|
December 2, 2004
The colony-stimulating factors: use to prevent and treat neutropenia and its complications
Rami S Komrokji, Gary H Lyman
Therapeutic Advances in Hematology
|
January 28, 2021
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Virginia O Volpe, Rami S Komrokji
Hematology (Amsterdam, Netherlands)
|
September 29, 2005
The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment
John M Bennett, Rami S Komrokji
Current Hematologic Malignancy Reports
|
April 29, 2010
Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification
Rami S Komrokji, John M Bennett
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Andrew T Kuykendall, Rami S Komrokji
Current Pharmaceutical Design
|
May 11, 2012
Lenalidomide for treatment of myelodysplastic syndromes
Rami S Komrokji, Alan F List
Expert Review of Hematology
|
June 15, 2018
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
Jamile M Shammo, Rami S Komrokji
Page
of 21